Cover Image
市場調查報告書

LEO Pharma A/S:產品平台分析

LEO Pharma A/S - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240928
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
LEO Pharma A/S:產品平台分析 LEO Pharma A/S - Product Pipeline Review - 2016
出版日期: 2016年05月11日 內容資訊: 英文 49 Pages
簡介

LEO Pharma A/S是針對皮膚科及血栓症的醫藥品進行藥物研發,開發,製造及商品化的獨立型醫藥品研究企業。

本報告提供LEO Pharma A/S的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

LEO Pharma A/S的基本資料

LEO Pharma A/S概要

  • 主要資訊
  • 企業資料

LEO Pharma A/S:研究開發概要

  • 主要的治療範圍

LEO Pharma A/S:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

LEO Pharma A/S:開發中產品概況

  • 後期開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

LEO Pharma A/S:藥物簡介

LEO Pharma A/S:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

LEO Pharma A/S:最近的開發平台趨勢

LEO Pharma A/S:暫停中的計劃

LEO Pharma A/S:開發中止的開發中產品

  • 開發中止的開發中產品簡介

LEO Pharma A/S:企業發表

LEO Pharma A/S:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08048CDB

Summary

Global Markets Direct's, 'LEO Pharma A/S - Product Pipeline Review - 2016', provides an overview of the LEO Pharma A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by LEO Pharma A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of LEO Pharma A/S
  • The report provides overview of LEO Pharma A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses LEO Pharma A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features LEO Pharma A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate LEO Pharma A/S's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for LEO Pharma A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding LEO Pharma A/S's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • LEO Pharma A/S Snapshot
    • LEO Pharma A/S Overview
    • Key Information
    • Key Facts
  • LEO Pharma A/S - Research and Development Overview
    • Key Therapeutic Areas
  • LEO Pharma A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • LEO Pharma A/S - Pipeline Products Glance
    • LEO Pharma A/S - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • LEO Pharma A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • LEO Pharma A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • LEO Pharma A/S - Drug Profiles
    • (betamethasone dipropionate + calcipotriene)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEO-43204
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • aprepitant
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ingenol mebutate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEO-124249
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LP-0113
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEO-130852A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEO-32731
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEO-39652
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-891
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LP-0067
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize MCHR1 for Weight Loss
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Protein Kinase C for Dermatology and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • LEO Pharma A/S - Pipeline Analysis
    • LEO Pharma A/S - Pipeline Products by Target
    • LEO Pharma A/S - Pipeline Products by Route of Administration
    • LEO Pharma A/S - Pipeline Products by Molecule Type
    • LEO Pharma A/S - Pipeline Products by Mechanism of Action
  • LEO Pharma A/S - Recent Pipeline Updates
  • LEO Pharma A/S - Dormant Projects
  • LEO Pharma A/S - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (calcipotriene + hydrocortisone butyrate)
      • TD-1414
  • LEO Pharma A/S - Company Statement
  • LEO Pharma A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • LEO Pharma A/S, Key Information
  • LEO Pharma A/S, Key Facts
  • LEO Pharma A/S - Pipeline by Indication, 2016
  • LEO Pharma A/S - Pipeline by Stage of Development, 2016
  • LEO Pharma A/S - Monotherapy Products in Pipeline, 2016
  • LEO Pharma A/S - Combination Treatment Modalities in Pipeline, 2016
  • LEO Pharma A/S - Partnered Products in Pipeline, 2016
  • LEO Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2016
  • LEO Pharma A/S - Pre-Registration, 2016
  • LEO Pharma A/S - Phase III, 2016
  • LEO Pharma A/S - Phase II, 2016
  • LEO Pharma A/S - Phase I, 2016
  • LEO Pharma A/S - Preclinical, 2016
  • LEO Pharma A/S - Discovery, 2016
  • LEO Pharma A/S - Pipeline by Target, 2016
  • LEO Pharma A/S - Pipeline by Route of Administration, 2016
  • LEO Pharma A/S - Pipeline by Molecule Type, 2016
  • LEO Pharma A/S - Pipeline Products by Mechanism of Action, 2016
  • LEO Pharma A/S - Recent Pipeline Updates, 2016
  • LEO Pharma A/S - Dormant Developmental Projects,2016
  • LEO Pharma A/S - Discontinued Pipeline Products, 2016
  • LEO Pharma A/S, Subsidiaries

List of Figures

  • LEO Pharma A/S - Pipeline by Top 10 Indication, 2016
  • LEO Pharma A/S - Pipeline by Stage of Development, 2016
  • LEO Pharma A/S - Monotherapy Products in Pipeline, 2016
  • LEO Pharma A/S - Partnered Products in Pipeline, 2016
  • LEO Pharma A/S - Pipeline by Top 10 Target, 2016
  • LEO Pharma A/S - Pipeline by Route of Administration, 2016
  • LEO Pharma A/S - Pipeline by Molecule Type, 2016
  • LEO Pharma A/S - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top